You are here: Industry Insights > Spravato

News List

EU approves expanded use of Janssen’s Spravato pharmatimes
February 09, 2021
The European Commission (EC) has approved the expanded use of Janssen’s Spravato for the rapid reduction of depressive symptoms in a psychiatric emergency, for adult patients with a moderate-to-severe episode of major depressive disorder (MDD).
Janssen disappointed with second NICE no for Spravato pharmatimes
September 04, 2020
Janssen says it is disappointed with second draft guidance from the National Institute for Health and Care Excellence (NICE) rejecting NHS funds for its nasal depression spray Spravato (esketamine).
Janssen Announces Approval of SPRAVATO for Major Depressive Disorder with Acute Suicidal Ideation americanpharmaceuticalreview
August 10, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant.
US FDA approves SPRAVATO, antidepressant medication from J&J expresspharma
August 05, 2020
The drug indicated to treat adults with major depressive disorder and acute suicidal ideation or behaviour reportedly begins improving depressive symptoms with the first dose.
New Data from SPRAVATO™ Studies Showed Rapid Reduction of Depressive Symptoms americanpharmaceuticalreview
September 10, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive results from two pivotal Phase 3 clinical studies (ASPIRE I & II) to evaluate the efficacy...
New data highlights value of Janssen’s Spravato pharmatimes
May 29, 2019
New data has illustrated the value of Janssen’s oral antidepressant Spravato (esketamine) CIII nasal spray for treatment-resistant depression (TRD).
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic worldpharmanews
March 07, 2019
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines...
FDA approves Janssen’s ketamine-based nasal antidepressant pharmaphorum
March 07, 2019
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to specialist clinics.
FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression drugs
March 06, 2019
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (t